Hyam I. Levitsky

11.8k citations

65 papers · 8.3k indexed · 4 hit papers · h-index 39

Immunology top 0.1%
- Immunotherapy and Immune Responses 47
- Immune Cell Function and Interaction 26
- T-cell and B-cell Immunology 23
Oncology top 0.5%
- CAR-T cell therapy research 17
- Cancer Immunotherapy and Biomarkers 9
Hematology top 2%
- Hematopoietic Stem Cell Transplantation 4
Biotechnology top 2%
Genetics top 2%
- Virus-based gene therapy research 8
Molecular Biology
- RNA Interference and Gene Delivery 6

Co-authors: Drew M. Pardoll Gang Zhou Alex Y. Huang Eduardo M. Sotomayor Robert J. Hayashi Ivan Borrello Elizabeth M. Jaffee Mojgan Ahmadzadeh
Cited by: Immunology Oncology Hematology
Partner nations: United States Georgia Singapore

In The Last Decade

Hyam I. Levitsky

64 papers receiving 8.1k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2004 Role of LAG-3 in Regulatory T Cells
1998 The Central Role of CD4+ T Cells in the Antitumor Immune Response
1998 Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
1994 Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens

Peers

Countries citing papers authored by Hyam I. Levitsky

Since Specialization

Citations

This map shows the geographic impact of Hyam I. Levitsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyam I. Levitsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyam I. Levitsky more than expected).

Fields of papers citing papers by Hyam I. Levitsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hyam I. Levitsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyam I. Levitsky. The network helps show where Hyam I. Levitsky may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hyam I. Levitsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hyam I. Levitsky Line = papers co-authored together Hyam I. Levitsky links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity Sabine Hoves,Chia-Huey Ooi,Carsten Wolter,Hadassah Sade,Stefan Bissinger,Martina Schmittnaegel,Oliver Ast,Anna Maria Giusti,Katharina Wartha,Valeria Runza,Wei Xu,Yvonne Kienast,Michael A. Cannarile,Hyam I. Levitsky,Solange Romagnoli,Michele De Palma,Dominik Rüttinger,Carola H. Ries	2018	153
2	TE-array—a high throughput tool to study transposon transcription Veena Gnanakkan,Andrew E. Jaffe,Lixin Dai,Jie Fu,Sarah J. Wheelan,Hyam I. Levitsky,Jef D. Boeke,Kathleen H. Burns	2013	9
3	Evaluation of Current Cancer Immunotherapy Christopher S. Hourigan,Hyam I. Levitsky	2011	15
4	K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate B. Douglas Smith,Yvette L. Kasamon,Jeanne Kowalski,Christopher D. Gocke,Kathleen M. Murphy,Carole B. Miller,Elizabeth Garrett‐Mayer,Hua-Ling Tsai,Qin Lu,Christina Y. Chia,Barbara Biedrzycki,Thomas C. Harding,Guang Haun Tu,Richard J. Jones,Kristen Hege,Hyam I. Levitsky	2010	77
5	Characterization of chronic myeloid leukemia stem cells Jonathan M. Gerber,Qin Lu,Jeanne Kowalski,B. Douglas Smith,Constance A. Griffin,Milada S. Vala,Michael I. Collector,Brandy Perkins,Marianna Zahurak,William Matsui,Christopher D. Gocke,Saul J. Sharkis,Hyam I. Levitsky,Richard J. Jones	2010	69
6	Magnetovaccination as a Novel Method to Assess and Quantify Dendritic Cell Tumor Antigen Capture and Delivery to Lymph Nodes Christopher M. Long,Hanneke W.M. van Laarhoven,Jeff W. M. Bulte,Hyam I. Levitsky	2009	74
7	Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments Justin Stebbing,Christopher G. Wood,Michael B. Atkins,Ronald M. Bukowski,Stephen D. Litwin,Mark Bower,Andrew T. Parsa,Hyam I. Levitsky	2008	4
8	Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance Gang Zhou,Hyam I. Levitsky	2007	174
9	Magnetoelectroporation: improved labeling of neural stem cells and leukocytes for cellular magnetic resonance imaging using a single FDA-approved agent Piotr Walczak,Jesús Ruı́z-Cabello,Dorota Kedziorek,Assaf A. Gilad,Sopo Lin,Brad P. Barnett,Qin Lu,Hyam I. Levitsky,Jeff W. M. Bulte	2006	63
10	Role of LAG-3 in Regulatory T Cellsbreakdown → Ching-Tai Huang,Creg J. Workman,Dallas B. Flies,Xiaoyu Pan,Aimee L. Marson,Gang Zhou,Edward L. Hipkiss,Sowmya Ravi,Jeanne Kowalski,Hyam I. Levitsky,Jonathan D. Powell,Drew M. Pardoll,Charles G. Drake,Dario A.A. Vignali	2004	993
11	Specific Immunotherapy by Genetically Engineered APCs: The “Guided Missile” Strategy Bo Wu,Jianming Wu,Alexei Miagkov,Robert N. Adams,Hyam I. Levitsky,Daniel B. Drachman	2001	18
12	Tumor‐specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines Franck Housseau,Daniël Langer,Samuel D. Oberholtzer,Anitha Moorthy,Hyam I. Levitsky,Drew M. Pardoll,Suzanne L. Topalian	2001	8
13	Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies William G. Nelson,Jonathan W. Simons,Bahar Mikhak,Ju-Fay Chang,Angelo M. De Marzo,Michael A. Carducci,Michael Kim,Christine E. Weber,Angelo A. Baccala,Marti A. Goeman,S Clift,Dale Ando,Hyam I. Levitsky,L. Cohen,Martin G. Sanda,Richard C. Mulligan,Alan W. Partin,H. Ballentine Carter,Steven Piantadosi,Fray F. Marshall	2000	62
14	Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes Zhengbin Lu,Lingxian Yuan,Xianzheng Zhou,Eduardo M. Sotomayor,Hyam I. Levitsky,Drew M. Pardoll	2000	169
15	A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous Tumor Cell-Based Vaccines Ivan Borrello,Eduardo M. Sotomayor,S. Cooke,Hyam I. Levitsky	1999	92
16	Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity David J. Morgan,Huub T. C. Kreuwel,Shonna Kaye Fleck,Hyam I. Levitsky,Drew M. Pardoll,Linda A. Sherman	1998	212
17	Tumors derived from antigen presenting cells Hyam I. Levitsky	1996	9
18	Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity Hyam I. Levitsky,Joel M. Montgomery,Mojgan Ahmadzadeh,Kevin F. Staveley-O’Carroll,Frank Guarnieri,Dario Livio Longo,Larry W. Kwak	1996	155
19	Tolerance and Cancer: A Critical Issue in Tumor Immunology Eduardo M. Sotomayor,Ivan Borrello,Hyam I. Levitsky	1996	54
20	In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. Hyam I. Levitsky,A Lazenby,Robert J. Hayashi,Drew M. Pardoll	1994	167

About Hyam I. Levitsky

Hyam I. Levitsky is a scholar working on Immunology, Oncology and Hematology, having authored 65 papers that have together received 8.3k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (47 papers), Immune Cell Function and Interaction (26 papers), T-cell and B-cell Immunology (23 papers), CAR-T cell therapy research (17 papers), Cancer Immunotherapy and Biomarkers (9 papers), Virus-based gene therapy research (8 papers), RNA Interference and Gene Delivery (6 papers) and Hematopoietic Stem Cell Transplantation (4 papers). The work is most often cited by research in Immunology (6.7k citations), Oncology (3.7k citations) and Hematology (451 citations). Hyam I. Levitsky has collaborated with scholars based in United States, Georgia and Singapore. Frequent co-authors include Drew M. Pardoll, Gang Zhou, Alex Y. Huang, Eduardo M. Sotomayor, Robert J. Hayashi, Ivan Borrello, Elizabeth M. Jaffee, Mojgan Ahmadzadeh, Kenneth E. Hung and Charles J. Lowenstein.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact